The risk factors for severe neutropenia in patients receiving mFOLFIRINOX were a low baseline WBC count and heterozygosity for UGT1A1*28 or UGT1A1*6 polymorphism. The gene discussed is UGT1A1; the disease is Decreased total neutrophil count.